Jones E A, Basile A S
Department of Gastrointestinal and Liver Diseases, Academic Medical Center, Amsterdam, The Netherlands.
Metab Brain Dis. 1998 Dec;13(4):351-60. doi: 10.1023/a:1020693026810.
The ammonia and GABAergic neurotransmission hypotheses of the pathogenesis of hepatic encephalopathy (HE) have appeared to be unrelated and perhaps mutually exclusive. Observations in animal models of fulminant hepatic failure, that are consistent with increased GABAergic inhibitory neurotransmission contributing to the manifestations of HE, include: (i) abnormal visual evoked potential waveforms that resemble those induced by GABA(A)/benzodiazepine (BZ) receptor complex agonists; (ii) GABA(A)/BZ receptor complex antagonist-induced ameliorations of encephalopathy; (iii) increased resistance to drugs which decrease GABAergic tone; and (iv) hypersensitivity of CNS neurons to depression by GABA(A)/BZ receptor complex agonists. Mechanisms of increased GABAergic tone in HE may include the following: (i) increased brain concentrations of natural BZs; and (ii) increased GABA concentrations in synaptic clefts, possibly due to increased blood-brain-barrier permeability to GABA and a decrease in GABA(B) receptor density. Both neuroelectrophysiological and behavioral data indicate that ammonia concentrations in the range 0.75-2 mM induce increased excitatory neurotransmission. In contrast, recently, ammonia concentrations in the range 0.15-0.75 mM, i.e. concentrations that commonly occur in plasma in precoma HE, have been shown: (i) to increase GABA-induced chloride current in cultured neurons; and (ii) to enhance synergistically the binding of GABA(A)/BZ receptor agonists. In addition, increased ammonia concentrations enhance synthesis of neurosteroids in astrocytes, and some neurosteroids potently augment GABAergic neurotransmission. Thus, the modestly elevated concentrations of ammonia, that commonly occur in liver failure, may contribute to the manifestations of HE by enhancing GABAergic inhibitory neurotransmission. This concept appears to unify the ammonia and GABAergic neurotransmission hypotheses.
肝性脑病(HE)发病机制的氨假说和GABA能神经传递假说似乎并无关联,甚至可能相互排斥。在暴发性肝衰竭动物模型中的观察结果表明,GABA能抑制性神经传递增加与HE的表现相关,这些观察结果包括:(i)异常视觉诱发电位波形,类似于GABA(A)/苯二氮䓬(BZ)受体复合物激动剂诱导的波形;(ii)GABA(A)/BZ受体复合物拮抗剂可改善脑病;(iii)对降低GABA能张力的药物的耐药性增加;(iv)中枢神经系统神经元对GABA(A)/BZ受体复合物激动剂的抑制作用过敏。HE中GABA能张力增加的机制可能包括以下几点:(i)脑内天然BZs浓度增加;(ii)突触间隙中GABA浓度增加,这可能是由于血脑屏障对GABA的通透性增加以及GABA(B)受体密度降低所致。神经电生理和行为学数据均表明,0.75 - 2 mM范围内的氨浓度会导致兴奋性神经传递增加。相比之下,最近研究发现,0.15 - 0.75 mM范围内的氨浓度,即昏迷前期HE患者血浆中常见的浓度,已被证明:(i)可增加培养神经元中GABA诱导的氯离子电流;(ii)协同增强GABA(A)/BZ受体激动剂的结合。此外,氨浓度升高会增强星形胶质细胞中神经甾体的合成,一些神经甾体可显著增强GABA能神经传递。因此,肝功能衰竭时常见的适度升高的氨浓度可能通过增强GABA能抑制性神经传递而导致HE的表现。这一概念似乎统一了氨假说和GABA能神经传递假说。